
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Novo Nordisk の市場拡大を追跡しています
過去 90 日間に 315 件のシグナル。
Novo Nordisk の海外展開を競合と比較
バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
Novo Nordisk自社 | 0 | 0 | — | 0 | 0 |
Supervisor, Business Intelligence
求人を見るTaipei, Taipei City, Taiwan · 今日
Senior IT/OT Solution Architect - API Expansion
求人を見るKalundborg, Region Zealand, Denmark · 今日
Pharma Field Sales - Cardiometabolic Care Specialist I - P Bakersfield North California
求人を見るBakersfield, CA · 5日前
Talk to a doctor
終了Talk to a doctor
終了Talk to a doctor
終了ブラジルの製薬会社EMSは6月15日に国産セマグルチドを発売。1本452レアルで、Ozempicなどの輸入品より30%安く、肥満治療へのアクセスを改善。
CaliWay BioPharmaがADA 2026でCBL-514の動物実験データを発表。GLP-1/RA薬との併用でリバウンドが2.7倍減少し、肝脂肪が106.7%追加減少。
ノボノルディスクが中国でソグロヤ(ソマパシタン)を発売。2.5歳以上の成長ホルモン欠乏症児童向けに週1回投与の長時間作用型成長ホルモンで、革新的な脂肪酸技術とPEGゼロ処方を特徴とする。
認証済みメールと直通電話を解放
無料 · カード不要
Novo Nordisk の事業、市場、成長シグナルに関する簡潔な回答。

© 2026 Pubrio. 無断転載を禁じます。